ACADIA Pharmaceuticals (ACAD) Stock Statistics & Valuation Metrics

ACADIA Pharmaceuticals has a market cap or net worth of $3.77B. The enterprise value is $3.64B.

ACADIA Pharmaceuticals has 167,361,850 shares outstanding. The number of shares has decreased by -2.65% in one year.

ACADIA Pharmaceuticals’s return on equity (ROE) is 0.31 and return on invested capital (ROIC) is 25.54%.

The current PE Ratio of ACADIA Pharmaceuticals is 13.43. ACADIA Pharmaceuticals’s PEG ratio is 22.67.

In the last 12 months, ACADIA Pharmaceuticals had revenue of 957.80M and earned 226.45M in profits. Earnings per share was 1.37.

In the last 12 months, operating cash flow was 148.96M and capital expenditures -99.36M, giving a free cash flow of 49.60M billion.

ACADIA Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―

ACADIA Pharmaceuticals upcoming earnings date is Jul 30, 2025, After Close (Confirmed).

ACADIA Pharmaceuticals as a current ratio of 2.38, with Debt / Equity ratio of 7.32%

In the past 12 months, ACADIA Pharmaceuticals has paid 31.62M in taxes.

ACADIA Pharmaceuticals EV to EBITDA ratio is 27.69, with an EV/FCF ratio of 17.64.

ACADIA Pharmaceuticals has $681.58M in cash and marketable securities with $56.01M in debt, giving a net cash position of -$625.57M billion.

Gross margin is 92.04%, with operating margin of 24.10%, and net profit margin of 23.64%.

The average price target for ACADIA Pharmaceuticals is $28.24, which is 11.43% higher than the current price. The consensus rating is Moderate Buy